Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Guillermo Burillo-Putze, John R. Richards, Consuelo Rodríguez-Jiménez & Alejandro Sanchez-Agüera. (2022) Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature. Expert Opinion on Pharmacotherapy 23:6, pages 693-702.
Read now
Read now
Samantha Wagner, Jason Hoppe, Matthew Zuckerman, Kerry Schwarz & Julie McLaughlin. (2020) Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department. Clinical Toxicology 58:6, pages 471-475.
Read now
Read now
Articles from other publishers (22)
Rachel S. Wightman, Jane Metrik, Timmy R. Lin, Yu Li, Adina Badea, Robert Almeida, Alexandra B. Collins & Francesca L. Beaudoin. (2023) Cannabis Use Patterns and Whole-Blood Cannabinoid Profiles of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome. Annals of Emergency Medicine 82:2, pages 121-130.
Crossref
Crossref
Jordan Kirby & Thileepan Naren. (2023) Cannabinoid hyperemesis syndrome in pregnancy: Challenges and opportunities. Australian and New Zealand Journal of Obstetrics and Gynaecology.
Crossref
Crossref
Rebecca B. Siegel, Sergey M. Motov & Evie G. Marcolini. (2023) Droperidol Use in the Emergency Department: A Clinical Review. The Journal of Emergency Medicine 64:3, pages 289-294.
Crossref
Crossref
Joe‐Anthony Rotella, Olivia G Ferretti, Elham Raisi, Hao Rui Seet & Soham Sarkar. (2022) Response to Re: Cannabinoid hyperemesis syndrome: A 6‐year audit of adult presentations to an urban district hospital. Emergency Medicine Australasia 35:1, pages 186-187.
Crossref
Crossref
Mohammad Razban, Aristomenis K. Exadaktylos, Vincent Della Santa & Eric P. Heymann. (2022) Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department. International Journal of Emergency Medicine 15:1.
Crossref
Crossref
Joe A Rotella, Olivia G Ferretti, Elham Raisi, Hao Rui Seet & Soham Sarkar. (2022) Cannabinoid hyperemesis syndrome: A 6‐year audit of adult presentations to an urban district hospital. Emergency Medicine Australasia 34:4, pages 578-583.
Crossref
Crossref
Helen Senderovich & Sarah Waicus. (2022) A Case Report on Cannabinoid Hyperemesis Syndrome in Palliative Care: How Good Intentions Can Go Wrong. Oncology Research and Treatment 45:7-8, pages 438-443.
Crossref
Crossref
Helen Senderovich, Preet Patel, Briam Jimenez Lopez & Sarah Waicus. (2022) A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options. Medical Principles and Practice 31:1, pages 29-38.
Crossref
Crossref
William L. Hasler, Thangam Venkatesan & David J. Levinthal. 2022. Cyclic Vomiting Syndrome and Cannabinoid Hyperemesis. Cyclic Vomiting Syndrome and Cannabinoid Hyperemesis
255
284
.
Heather Murray & Thida Thant. 2022. Cannabis in Psychiatric Practice. Cannabis in Psychiatric Practice
153
163
.
Sergey M. Motov, Katherine Vlasica, Igor Middlebrook & Alexis LaPietra. (2021) Pain management in the emergency department: a clinical review. Clinical and Experimental Emergency Medicine 8:4, pages 268-278.
Crossref
Crossref
Kevin M. Takakuwa & Raquel M. Schears. (2021) The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. International Journal of Emergency Medicine 14:1.
Crossref
Crossref
Joseph Wesley WatkinsIVIV & Zachary Bert Lewis. (2021) Diagnoses of Exclusion in the Workup of Abdominal Complaints. Emergency Medicine Clinics of North America 39:4, pages 851-863.
Crossref
Crossref
Jonathan Cordova, Vincent Biank, Elizabeth Black & Jerrold Leikin. (2021) Urinary Cannabis Metabolite Concentrations in Cannabis Hyperemesis Syndrome. Journal of Pediatric Gastroenterology & Nutrition 73:4, pages 520-522.
Crossref
Crossref
George Sam Wang, Christine Buttorff, Asa Wilks, Daniel Schwam, Gregory Tung & Rosalie Liccardo Pacula. (2021) Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado. JAMA Network Open 4:9, pages e2125063.
Crossref
Crossref
Aaron J. Ruberto, Marco L.A. Sivilotti, Savannah Forrester, Andrew K. Hall, Frances M. Crawford & Andrew G. Day. (2021) Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Annals of Emergency Medicine 77:6, pages 613-619.
Crossref
Crossref
Nathaniel Leu & Joanne C. Routsolias. (2021) Cannabinoid Hyperemesis Syndrome: A Review of the Presentation and Treatment. Journal of Emergency Nursing 47:3, pages 483-486.
Crossref
Crossref
Julie Weiss, Romain Torrents, Baptiste Verhamme, Antoine Roch, Pierre Lazerges, Maeva Jego, Pierre Michelet & Nicolas Simon. (2020) Cannabinoid hyperemesis syndrome in two French emergency departments: a prospective cohort. Fundamental & Clinical Pharmacology 35:1, pages 186-191.
Crossref
Crossref
Brad E. Schwartz, Karen Keller Baker, Andrew J. Bleinberger, Amina Lleshi & Raul Cruz-Cano. (2021) Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis. World Journal of Emergency Medicine 12:3, pages 228.
Crossref
Crossref
Diana J. Dean, Noor Sabagha, Kaitlin Rose, Alexander Weiss, John France, Timothy Asmar, Jo‐Ann Rammal, Margaret Beyer, Rebecca Bussa, Jacob Ross, Kaleem Chaudhry, Thomas Smoot, Kathleen Wilson & Joseph Miller. (2020) A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome. Academic Emergency Medicine 27:11, pages 1166-1172.
Crossref
Crossref
Alicia Mattson, Kimberly Friend, Caitlin S Brown & Daniel Cabrera. (2020) Reintegrating droperidol into emergency medicine practice. American Journal of Health-System Pharmacy 77:22, pages 1838-1845.
Crossref
Crossref
. (2019) Droperidol. Reactions Weekly 1770:1, pages 158-158.
Crossref
Crossref